natgillin/translations-raw huggingface dataset:
These events are often transitory.
Ti učinki so pogosto prehodni.
Interaction (mechanism, if known)
Medsebojno delovanje (mehanizem, če je znan)
Currently available data are described in sections 5.1 and 5.2.
Podatki, ki so trenutno na voljo, so opisani v poglavjih 5.1 in 5.2.
Notes: The analysis is based on all available data.
Opombe: Analiza temelji na vseh podatkih, ki so na voljo.
These measures will help protect the
Taki ukrepi pomagajo varovati okolje.
No fatalities occurred, and the patients recovered.
Smrtnih primerov ni bilo in vsi bolniki so okrevali.
The observed half-life of elimination is 5 to 7 hours.
Ugotovljeni eliminacijski razpolovni čas je od 5 do 7 ur.
The long-term consequences of these events are currently unknown.
Dolgoročne posledice tega trenutno niso znane.
Reducing the amount of HIV in the blood may improve the functioning of your immune system.
Zmanjšanje količine virusa HIV v krvi lahko izboljša delovanje imunskega sistema.
It can be life-threatening, and cause internal organs to fail.
Lahko je življenjsko nevarna in lahko povzroči odpoved notranjih organov.
Final dose population N=96
Populacija s končnim odmerkom N = 96
• This medicine can be taken with or without food or drink.
• To zdravilo lahko jemljete skupaj s hrano ali pijačo ali brez njiju.
Patients at increased risk should be followed closely.
Bolnike z večjim tveganjem je treba skrbno spremljati.
This means your body may fight infection better.
To pomeni, da lahko telo bolje premaguje okužbe.
Talk to your doctor about other medicines you can take.
Z zdravnikom se posvetujte glede drugih zdravil, ki jih lahko jemljete.
Green, oval tablet, marked with "144" on one side.
zelena, ovalna tableta, z oznako "144" na eni strani
BENCHMRK 1 and 2 Pooled
Združeni podatki študij BENCHMRK 1 in 2
Lactic acidosis generally occurred after a few or several months of treatment.
Laktacidoza se je običajno pojavila po nekaj ali več mesecih zdravljenja.
Raltegravir has a relatively low genetic barrier to resistance.
Raltegravir ima razmeroma majhno genetsko bariero za odpornost.
Biotransformation and excretion
Biotransformacija in izločanje
Percent of patients with response and associated 95 % confidence interval (CI) are reported.
Naveden je odstotek bolnikov z odzivom in pripadajoči 95-odstotni interval zaupanja (IZ).
• increase your CD4-cell count (a type of white blood cell that plays an important role in maintaining a healthy immune system to help fight infection).
• poveča število celic CD4 (vrsta belih krvnih celic, ki imajo pomembno vlogo pri vzdrževanju zdravega imunskega sistema, ki se bori proti okužbi).
In these 96 children and adolescents, frequency, type and severity of drug related adverse reactions through Week 48 were comparable to those observed in adults.
Pri teh 96 otrocih in mladostnikih so bile pogostnost, vrsta in resnost z zdravilom povezanih neželenih učinkov do 48. tedna primerljive s tistimi, ki so jih opazili pri odraslih.
It is rare (may affect up to 1 in 1,000 people) and if it does happen, it usually happens after a few months of treatment.
Je redka (pojavi se lahko pri največ 1 od 1.000 bolnikov) in če se razvije, se to običajno zgodi po nekaj mesecih zdravljenja.
After dose selection, additional patients were enrolled for evaluation of long term safety, tolerability and efficacy.
Po izbiri odmerka so bili za oceno dolgotrajne varnosti, prenašanja in učinkovitosti vključeni dodatni bolniki.
• certain kinds of kidney problems, including conditions in which the kidneys lose the ability to remove waste and excess water from the bloodstream.
• določene vrste težav z ledvicami, vključno s stanji, ko ledvice izgubijo sposobnost za odstranjevanje odpadnih snovi in odvečne vode iz krvnega obtoka.
Patients were stratified by age, enrolling adolescents first and then successively younger children.
Bolnike so razvrstili glede na starost, najprej so vključili mladostnike in nato vedno mlajše otroke.
The recommended dose is 1 tablet twice a day.
Priporočeni odmerek je 1 tableta dvakrat na dan.
(chelation of metal cations)
(kelacija kovinskih kationov)
However, it is not clear whether these cases were due to the ART or to the underlying HIV disease.
Vendar ni jasno, ali so bili ti primeri posledica protiretrovirusnega zdravljenja ali osnovne bolezni HIV.
These studies were terminated after the primary efficacy analysis at Week 24 because they failed to demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir.
Študiji so končali po primarni analizi učinkovitosti 24. teden, ker nista pokazali neinferiornosti raltegravirja v primerjavi z lopinavirjem (+) ritonavirjem.
• feeling tired, lack of energy, difficulty in sleeping (insomnia)
• utrujenost, pomanjkanje energije, težave s spanjem (nespečnost)
This is not considered to be of significance to patient safety and therefore no dosage adjustments are necessary.
To velja za nepomembno za varnost bolnikov, zato prilagoditve odmerkov niso potrebne.
Some patients experienced viral rebound between Week 16 and Week 96.
Pri nekaterih bolnikih se je med 16. in 96. tednom pojavil virusni preobrat.
After first opening of the medicinal product, the in-use shelf life is 30 days, below 30°C.
Po prvem odprtju zdravila je rok uporabnosti med uporabo 30 dni, pri shranjevanju do 30 °C.
126 treatment experienced children and adolescents 2 to 18 years of age.
Študija je zajela 126 že zdravljenih otrok in mladostnikov, starih od 2 do 18 let.
Severe skin and hypersensitivity reactions
Hude kožne in preobčutljivostne reakcije
• reduce the amount of HIV in your blood (this is called your "viral load")
• zmanjša količino virusa HIV v krvi (ki jo imenujemo "virusna obremenitev"),
Patients should be advised that current antiretroviral therapy does not cure HIV and has not been proven to prevent the risk of transmission of HIV to others through blood contact.
Bolnikom je treba pojasniti, da trenutni načini protiretrovirusnega zdravljenja okužbe z virusom HIV ne pozdravijo, in da ni bilo dokazano, da bi preprečili tveganje za prenos virusa HIV na druge s krvjo.
It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Domnevno so ti simptomi posledica izboljšanja telesnega imunskega odziva, ki telesu omogoči, da se spopade z okužbami, ki so bile pred tem morda prisotne brez opaznih simptomov.
48 Weeks
48 tednov
The maximum dose is one tablet twice daily.
Največji odmerek je ena tableta dvakrat na dan.
• It is very important to take all your HIV medicines as prescribed and at the right times of day.
• je zelo pomembno, da vsa zdravila za zdravljenje okužbe z virusom HIV jemljete natančno po zdravnikovih navodilih in ob predpisanem času.
These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.
To vključuje primere Stevens-Johnsonovega sindroma in toksične epidermalne nekrolize.
Whether the neurological disorders are transient or permanent is currently unknown.
Trenutno ni znano, ali so te nevrološke motnje prehodne ali trajne.
Patients with HIV are at higher risk of developing cancer than patients without the disease.
Pri bolnikih, okuženih s HIV, obstaja večje tveganje za pojav raka kot pri bolnikih brez okužbe.
• you have had problems with your liver before, including hepatitis B or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take this medicine.
• če ste kdaj imeli težave z jetri, vključno s hepatitisom B ali C. Zdravnik bo morda z ustreznimi preiskavami ocenil, kako hudo bolezen jeter imate, preden se bo odločil, ali lahko jemljete to zdravilo.
Raltegravir and efavirenz were administered with emtricitabine (+) tenofovir.
Raltegravir in efavirenz sta bila uporabljena z emtricitabinom (+) tenofovirjem.
Any inflammatory symptoms should be evaluated and treatment instituted when necessary.
Kakršne koli simptome vnetja je treba obravnavati in uvesti zdravljenje, kadar je potrebno.
Following oral administration, lamivudine pharmacokinetics in late pregnancy were similar to non-pregnant women.
Po peroralni uporabi je bila farmakokinetika lamivudina v pozni nosečnosti podobna kot pri ženskah, ki niso noseče.
• abnormal dreams; nightmare; abnormal behaviour; feelings of deep sadness and
• nenormalne sanje, nočne more, nenormalno obnašanje, občutki globoke žalosti in
The risk of developing cancer in these studies was similar in the groups receiving raltegravir and in the groups receiving comparators.
Tveganje za pojav raka je bilo v teh študijah podobno v skupinah, ki so prejemale raltegravir, in v skupinah, ki so prejemale primerjalna zdravila.
Recommendations are based on available data from the individual components.
Priporočila temeljijo na podatkih, ki so na voljo za posamezni učinkovini.
HIV infection is spread by contact with blood or sexual contact with a person with HIV.
Do okužbe z virusom HIV lahko pride pri stiku z okuženo krvjo ali spolnem odnosu z osebo, okuženo z virusom HIV.
There are no adequate data from the use of raltegravir in pregnant women; however, a large amount of data on pregnant women who were administered lamivudine (more than 1,000 exposed outcomes) indicate no malformative toxicity.
O uporabi raltegravirja pri nosečnicah ni zadostnih podatkov, toda velika količina podatkov o nosečnicah, ki so prejemale lamivudin (več kot 1.000 izidov po izpostavljenosti), ne kaže malformacijskih toksičnih učinkov.
This may mean that the HIV virus will develop resistance to DUTREBIS and become harder to treat.
To lahko pomeni, da bo virus HIV postal odporen na zdravilo DUTREBIS in okužbo bo težje zdraviti.
Do not take DUTREBIS:
Ne jemljite zdravila DUTREBIS:
During your treatment, your doctor will check you for signs of lactic acidosis.
Med zdravljenjem vas bo zdravnik opazoval glede znakov laktacidoze.
If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same
Če predložitev PSUR in posodobitev RMP sovpadata, se lahko predložita sočasno.
• you have a history of depression or psychiatric illness.
• če ste kdaj imeli depresijo ali kakšno duševno bolezen.
• If you are allergic to lamivudine, raltegravir or any of the other ingredients in this medicine listed in section 6.
• če ste alergični na lamivudin, raltegravir ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
• liver failure (the liver stops working , which may cause heavy bleeding, swelling, and
• odpoved jeter (jetra prenehajo delovati, kar lahko povzroči hude krvavite, otekanje in
• rifampicin - used to treat some infections such as tuberculosis.
• rifampicin - uporablja se za zdravljenje nekaterih okužb, na primer tuberkuloze.
HIV-RNA > 100,000 copies/ml
HIV-RNA > 100.000 kopij/ml
Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare
pogosti (od ≥ 1/100 do < 1/10), občasni (od ≥ 1/1.000 do < 1/100), redki (od ≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
Physicians are encouraged to register patients in this registry.
Zdravnike prosimo, da takšne bolnice zabeležijo v ta
As a general rule, it is recommended that mothers infected by HIV do not breast-feed their babies in order to avoid transmission of HIV.
Praviloma je priporočljivo, da z virusom HIV okužene matere ne dojijo svojih dojenčkov in tako preprečijo prenos virusa HIV.
People taking anti-retroviral medicines may find that their body shape changes.
Osebam, ki jemljejo protiretrovirusna zdravila, se lahko spremeni oblika telesa.
The following drug interaction information is based on Geometric Mean values; the effect for an individual patient cannot be predicted precisely.
V nadaljevanju navedeni podatki o medsebojnem delovanju z drugimi zdravili temeljijo na geometričnih povprečnih vrednostih, vendar pa učinka pri posameznem bolniku ni možno natančno predvideti.
This enzyme is needed for HIV to make more virus.
Virus HIV potrebuje ta encim za nastajanje novih virusov.
The tablets should be swallowed whole, without crushing or chewing.
Tablete je treba zaužiti cele, brez drobljenja ali žvečenja.
Based on modelling and simulation using raltegravir pharmacokinetic data in adults, the pharmacokinetics of raltegravir in DUTREBIS in children was projected to result in exposures that have been previously shown to be safe and efficacious in adults.
Na podlagi modeliranja in simulacij z uporabo farmakokinetičnih podatkov o raltegravirju pri odraslih, farmakokinetika raltegravirja v zdravilu DUTREBIS pri otrocih predvidoma doseže izpostavljenosti, ki so bile pri odraslih predhodno ugotovljene kot varne in učinkovite.
This can help your medicines work better.
Na ta način bo delovanje vseh zdravil boljše,
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance (> 70 %) via the organic cationic transport system.
Povprečen sistemski očistek lamivudina je približno 0,32 l/h/kg, predvsem z ledvičnim očistkom (> 70 %) preko transportnega sistema organskih
Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85 %.
Lamivudin se dobro absorbira iz prebavil in biološka uporabnost peroralno uporabljenega lamivudina pri odraslih je ponavadi med 80 in 85 %.
This is slightly faster than the raltegravir poloxamer formulation, which has a Tmax of approximately 3 hours.
To je nekoliko hitreje kot raltegravirjev poloksamer, ki ima tmax približno 3 ure.
The M184V RT mutant shows a <4-fold decrease in susceptibility to didanosine; the clinical significance of these findings is unknown.
Mutant M184V RT kaže < 4-kratno zmanjšanje občutljivosti na didanozin; klinični pomen teh izsledkov ni znan.
Most viruses isolated from patients failing raltegravir had high-level raltegravir resistance resulting from the appearance of two or more mutations.
Večina virusov, izoliranih pri bolnikih, ki se niso odzvali na zdravljenje z raltegravirjem, je imela visoko stopnjo odpornosti na raltegravir, ki je bila posledica pojava dveh ali več mutacij.
Excipient with known effect: Each tablet contains 39.70 mg lactose (as monohydrate).
Pomožna snov z znanim učinkom: Ena tableta vsebuje 39,70 mg laktoze (v obliki monohidrata).
In intravenous studies with lamivudine, the mean volume of distribution is 1.3 l/kg.
Študije intravenske uporabe lamivudina so pokazale povprečen volumen porazdelitve 1,3 l/kg.
DUTREBIS film-coated tablets contain lactose.
Zdravilo DUTREBIS filmsko obložene tablete vsebuje laktozo.
For analysis by prognostic factors, virologic failures were carried forward for percent < 400 and 50 copies/ml.
Pri analizi po prognostičnih dejavnikih so vrednosti za virološki neuspeh prenesli k odstotku < 400 in 50 kopij/ml.
Patients received either the 400 mg tablet formulation (6 to 18 years of age) or the chewable tablet formulation (2 to less than 12 years of age).
Bolniki so prejeli zdravilo v obliki 400-mg tablet (od 6 do 18 let) ali v obliki žvečljivih tablet (od 2 do manj kot 12 let).
These median proportions are approximately 3- to 6-fold lower than the free fraction of raltegravir in plasma.
Ti mediani deleži so približno 3- do 6-krat nižji od proste frakcije raltegravirja v plazmi.
• taking drug in quantities greater than recommended These are rare (may affect up to 1 in 1,000 people)
• jemanje večje količine zdravila, kot je priporočeno Ti so redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov)
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
V primeru sočasnega protivirusnega zdravljenja proti hepatitisu B ali C je treba upoštevati tudi ustrezne informacije o teh zdravilih.
Based on these data, raltegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of these enzymes or P-glycoprotein.
Na osnovi teh podatkov ni pričakovati, da bi raltegravir vplival na farmakokinetiko zdravil, ki so substrati za te encime ali P-glikoprotein.
Most had a signature mutation at amino acid 155 (N155 changed to H), amino acid 148 (Q148 changed to H, K, or R), or amino acid 143 (Y143 changed to H, C, or R), along with one or more additional integrase mutations (e.g., L74M, E92Q, T97A, E138A/K, G140A/S, V151I, G163R, S230R).
Pri večini so bile prisotne mutacije aminokisline 155 (N155 sprememba na H), aminokisline 148 (Q148 sprememba na H, K ali R) ali aminokisline 143 (Y143 sprememba na H, C ali R) skupaj s še eno ali več dodatnimi mutacijami integraze (npr. L74M, E92Q, T97A, E138A/K, G140A/S, V151I, G163R, S230R).
In addition, higher C12h levels (20 % for raltegravir and 53 % for lamivudine) were observed.
Poleg tega so ugotovili višjo vrednost C12ur (20 % za raltegravir in 53 % za lamivudin).
In vitro susceptibility testing has not been standardised and results may vary according to methodological factors.
Testiranje občutljivosti in vitro ni standardizirano in rezultati se lahko razlikujejo glede na
Additionally, renal insufficiency was evaluated in the composite pharmacokinetic analysis.
Poleg tega so insuficienco ledvic ocenili v sestavljeni farmakokinetični analizi.
• This medicine has been prescribed for you or your child only.
• Zdravilo je bilo predpisano vam ali vašemu otroku osebno in ga ne smete dajati drugim.
DUTREBIS tablets can be administered with or without food.
Tablete zdravila DUTREBIS je mogoče vzeti s hrano ali brez nje.
Dose selection was based upon achieving similar raltegravir plasma exposure and trough concentration as seen in adults, and acceptable short term safety.
Izbira odmerka je temeljila na doseganju podobne plazemske izpostavljenosti raltegravirju in podobne najmanjše koncentracije kot pri odraslih in na sprejemljivi kratkoročni varnosti.
Randomization was stratified by screening HIV RNA level (≤50,000 copies/ml; and > 50,000 copies/ml) and by hepatitis B or C status (positive or negative).
Randomizacija je bila stratificirana po koncentraciji HIV RNA ob presejanju (≤ 50.000 kopij/ml in > 50.000 kopij/ml) ter po statusu hepatitisa B ali C (pozitiven ali negativen).
Effects at exposure levels sufficiently in excess of clinical exposure levels indicate no special hazard for humans.
Učinki pri izpostavljenosti, ki je dovolj presegala izpostavljenost pri klinični uporabi, ne kažejo posebnega tveganja za človeka.
The initial dose finding stage included intensive pharmacokinetic evaluation.
Faza določitve začetnega odmerka je vključevala obsežno ovrednotenje farmakokinetike.
See a doctor immediately, if you notice any of the following: These are uncommon (may affect up to 1 in 100 people)
Če opazite kaj od naslednjega, takoj obiščite zdravnika: Ti so občasni (pojavijo se lahko pri največ 1 od 100 bolnikov)
MSD + logo
MSD + logotip
However, the magnitude of the effect seems unlikely to result in clinically important drug-drug interactions.
Vendar glede na obseg tega učinka ni verjetno, da bi povzročil klinično pomembna medsebojna delovanja med zdravili.
Sources of variability within the BENCHMRK study may include differences in co-administration with food and concomitant medicines.
Razlogi za variabilnost v študiji BENCHMRK so lahko razlike v sočasnem jemanju s hrano in sočasno uporabljanimi zdravili.
It is important that you take DUTREBIS exactly as your doctor has instructed.
Pomembno je, da tablete DUTREBIS jemljete natanko tako, kot vam je naročil zdravnik.
Achieved ≥1 log10 HIV RNA drop from baseline or
Dosežen ≥ 1 log10 padec HIV RNA od izhodišča
• kidney stones; urination at night; kidney cyst
• ledvični kamni, uriniranje ponoči, ledvična cista
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Praviloma so takšne reakcije opažali v prvih nekaj tednih ali mesecih po začetku kombiniranega protiretrovirusnega zdravljenja.
Pack size: 1 bottle containing 60 tablets.
Velikost pakiranja: 1 plastenka s 60 tabletami.
Clinical examination should include evaluation for physical signs of fat redistribution.
Klinični pregled mora obsegati tudi iskanje telesnih znakov prerazporeditve maščevja.
zidovudine Cmax  28 % zidovudine AUC ↔
Cmax zidovudina  28 % AUC zidovudina ↔
Tell your doctor if you notice any of the following signs of osteonecrosis:
Zdravnika morate obvestiti, če opazite katerega od naslednjih znakov osteonekroze:
This may be more likely with long-term HIV treatment, more severe damage to the immune system, overweight, or the use of alcohol or other medicines called corticosteroids.
To je verjetneje med dolgotrajnim zdravljenjem HIV, v primeru hude okvare imunskega sistema, prekomerne telesne teže ter uživanja alkohola ali drugih zdravil, imenovanih kortikosteroidi.
Of the 126 patients, 96 received the recommended dose of raltegravir (see section 4.2).
Od 126 bolnikov jih je 96 prejemalo priporočeni odmerek raltegravirja (glejte poglavje 4.2).
Safety profiles in the subgroup of patients in Phase III studies taking proton pump inhibitors or H2 antagonists were comparable with those who were not taking these antacids.
Varnostni profili v podskupini bolnikov v kliničnih študijah III. faze, ki so jemali zaviralce protonske črpalke ali antagoniste H2, so bili primerljivi s tistimi pri bolnikih, ki niso jemali teh antacidov.
The mean (CV) AUC over a dosing interval of 12 hours is 4.7 μg•h/ml (18 %).
Povprečna vrednost AUC (KV) v odmernem intervalu 12 ur je 4,7 µg•h/ml (18 %).
What you need to know before you take DUTREBIS
Kaj morate vedeti, preden boste vzeli zdravilo DUTREBIS
Exposure (AUC∞), Cmax, and half-life increased with diminishing renal function (as expressed by creatinine clearance).
Izpostavljenost (AUC∞), Cmax in razpolovni čas so se povečevali z zmanjševanjem delovanja ledvic (izraženim z očistkom kreatinina).
Lipid disorders should be managed as clinically appropriate (see section 4.8).
Motnje lipidov je treba obravnavati, kot je klinično ustrezno (glejte poglavje 4.8).
The apparent terminal half-life of raltegravir is approximately 9 hours, with a shorter α-phase half-life (~1 hour) accounting for much of the AUC.
Navidezni razpolovni čas raltegravirja je približno 9 ur s krajšim razpolovnim časom α-faze (~1 ura), ki predstavlja velik del AUC.
With twice-daily dosing of raltegravir, pharmacokinetic steady state is achieved rapidly, within approximately the first 2 days of dosing.
Med uporabo raltegravirja dvakrat na dan je farmakokinetično stanje dinamičnega ravnovesja doseženo hitro, v približno prvih 2 dneh uporabe.
Non-completer is failure imputation: patients who discontinued prematurely are imputed as failure thereafter.
Nedokončano zdravljenje je označeno kot neuspešno: zdravljenje pri bolnikih, ki so predčasno prenehali z zdravljenjem, je tako označeno kot neuspešno.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko pomanjkanja laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
What DUTREBIS is and what it is used for What you need to know before you take DUTREBIS
Kaj je zdravilo DUTREBIS in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo DUTREBIS
If you take more DUTREBIS than you should Do not take more tablets than the doctor recommends.
Če ste vzeli večji odmerek zdravila DUTREBIS, kot bi smeli Ne vzemite večjega števila tablet, kot vam jih je predpisal zdravnik.
As waste and fluids accumulate, other body systems are affected, potentially leading to complications
Kopičenje odpadnih snovi in tekočin prizadene še druge organske sisteme in lahko povzroči zaplete.
However, raltegravir is secreted in the milk of lactating rats.
Vendar se raltegravir izloča v mleko doječih podgan.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment should be considered.
Če se pri takšnih bolnikih pojavijo znaki poslabšanja bolezni jeter, je treba razmisliti o začasni ali trajni prekinitvi zdravljenja.
DUTREBIS must not be used with the following medicines.
Zdravila DUTREBIS se ne sme uporabljati z naslednjimi zdravili.